164 related articles for article (PubMed ID: 32750414)
21. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
23. [SCCOHT/ovarian rhabdoid tumor: A case report].
Bourgoin R; Cornelis F; Masliah-Planchon J; Genestie C; Laé M
Ann Pathol; 2019 Sep; 39(5):357-363. PubMed ID: 30928254
[TBL] [Abstract][Full Text] [Related]
24. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM
Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001
[TBL] [Abstract][Full Text] [Related]
25. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L; Goudie C; Ramos P; Boshari T; Brunet JS; Karnezis AN; Longy M; Knost JA; Saloustros E; McCluggage WG; Stewart CJR; Hendricks WPD; Cunliffe H; Huntsman DG; Pautier P; Levine DA; Trent JM; Berchuck A; Hasselblatt M; Foulkes WD
Gynecol Oncol; 2016 Jun; 141(3):454-460. PubMed ID: 26975901
[TBL] [Abstract][Full Text] [Related]
26. Small Cell Carcinoma of the Ovary, Hypercalcemic Type, in a 12-Month-Old Girl.
Atwi D; Quinton MR; Kiser RM; Pokala HR; Rooms LM; Yu Z
Pediatr Dev Pathol; 2021; 24(5):493-497. PubMed ID: 34047234
[TBL] [Abstract][Full Text] [Related]
27. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
[TBL] [Abstract][Full Text] [Related]
28. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
[TBL] [Abstract][Full Text] [Related]
29. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
[TBL] [Abstract][Full Text] [Related]
30. [The value of immunohistochemistry using SMARCA4/BRG1 in the diagnosis of small cell ovarian carcinoma hypercalcemic type. A report of two cases].
Ruiz-García G; Torroba-Carón MA; Ferri-Ñíguez B; Lencina-Guardiola M; García-Molina F; Martínez-Barba E
Rev Esp Patol; 2018; 51(1):61-67. PubMed ID: 29290327
[TBL] [Abstract][Full Text] [Related]
31. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
Blatnik A; Dragoš VŠ; Blatnik O; Stegel V; Klančar G; Novaković S; Drev P; Žagar T; Merlo S; Škof E; Bojadžiski MP; Strojnik K; Krajc M
Arch Pathol Lab Med; 2024 Mar; 148(3):299-309. PubMed ID: 37270804
[TBL] [Abstract][Full Text] [Related]
32. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD
Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340
[TBL] [Abstract][Full Text] [Related]
33. Case Report of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (Ovarian Rhabdoid Tumor) with
Simões MFE; da Costa AABA; Silva TN; Fernandes L; Bovolim G; Torrezan GT; Carraro DM; Baiocchi G; Menezes ANO; Santana Dos Santos E; De Brot L
Curr Oncol; 2022 Jan; 29(2):411-422. PubMed ID: 35200537
[TBL] [Abstract][Full Text] [Related]
34. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
[TBL] [Abstract][Full Text] [Related]
35. Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Pressey JG; Dandoy CE; Pater LE; Sroga Rios J; Sisson R; Dasgupta R; Szabo S
Gynecol Oncol; 2020 Sep; 158(3):538-546. PubMed ID: 32654763
[TBL] [Abstract][Full Text] [Related]
36. Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type.
David MP; Venkatramani R; Lopez-Terrada DH; Roy A; Patil N; Fisher KE
Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 30275002
[TBL] [Abstract][Full Text] [Related]
37. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
Ramalingam P; Croce S; McCluggage WG
Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
[TBL] [Abstract][Full Text] [Related]
38. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
[TBL] [Abstract][Full Text] [Related]
39. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L; Carrot-Zhang J; Albrecht S; Fahiminiya S; Hamel N; Tomiak E; Grynspan D; Saloustros E; Nadaf J; Rivera B; Gilpin C; Castellsagué E; Silva-Smith R; Plourde F; Wu M; Saskin A; Arseneault M; Karabakhtsian RG; Reilly EA; Ueland FR; Margiolaki A; Pavlakis K; Castellino SM; Lamovec J; Mackay HJ; Roth LM; Ulbright TM; Bender TA; Georgoulias V; Longy M; Berchuck A; Tischkowitz M; Nagel I; Siebert R; Stewart CJ; Arseneau J; McCluggage WG; Clarke BA; Riazalhosseini Y; Hasselblatt M; Majewski J; Foulkes WD
Nat Genet; 2014 May; 46(5):438-43. PubMed ID: 24658002
[TBL] [Abstract][Full Text] [Related]
40. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
